

Global Atopic Dermatitis Treatment Market is on track to achieve a staggering US\$ 7.6 Billion in revenue by 2029 | FMI

USA dominates 90% of North America's atopic dermatitis treatment market due to rising patient numbers, climate shifts, and medical advancements.

NEWARK, DELAWARE, UNITED STATES OF AMERICA, November 17, 2023 /EINPresswire.com/ -- The global [atopic dermatitis treatment market](#), which was valued at US\$ 5.2 billion in 2021, is anticipated to showcase robust growth, reaching US\$ 7.6 billion by 2029. According to industry projections, this market is expected to grow at a steady CAGR of 4.8% between 2022 and 2029.



Atopic Dermatitis, a prevalent chronic skin condition affecting millions worldwide, has been a significant concern within the healthcare landscape. The increasing prevalence of this condition has sparked notable advancements in treatment options, leading to a significant market expansion.

Request a Sample Copy of the Report Now:

<https://www.futuremarketinsights.com/reports/sample/rep-gb-3097>

The rise in demand for effective treatments and therapies to address the symptoms associated with Atopic Dermatitis has been a key driver for this market's growth. Manufacturers and pharmaceutical companies are actively investing in research and development to introduce innovative solutions, contributing to the market's positive trajectory.

Factors contributing to the market's expansion include increased awareness about the condition, rising healthcare expenditure, and the introduction of novel therapies that aim to alleviate symptoms and improve patients' quality of life.

The market's growth is expected to witness regional variations, driven by evolving treatment preferences, regulatory frameworks, and the adoption of advanced healthcare technologies.

Corticosteroids Remain the Drug of Choice:

Corticosteroids are referred as the first choice of treatment for the inflammation and pain relief. These medications are known to have effects, for example, decreasing tingling, allergic reaction,

swelling and redness.

Around 30 corticosteroid compounds have been licensed for atopic dermatitis treatment, of which 'hydrocortisone' is considered as the first. In addition, increasing innovations have resulted in the advent of topical non-corticosteroids immunomodulators and target medications, for example, immunomodulators such as pimecrolimus and tacrolimus, which in turn, is likely to fuel the growth of the atopic dermatitis treatment market. Moreover, topical corticosteroids are expected to play an important roles in the atopic dermatitis treatment.

North America to Offer High Sales Opportunities:

Growth prospects of the atopic dermatitis treatment market are likely to be high in North America over the forecast period of 2022-2029. Factors such as, greater treatment awareness among the patient population across the United States and Canada, early adoption of novel prescriptions, advanced healthcare infrastructure, better and favorable reimbursement policies, and increasing business associations of pharmaceutical organizations with contract research organizations in developing markets will continue to propel the atopic dermatitis treatment market growth. Despite the fact that the U.S and Canada deal with heavy investment in healthcare infrastructure as well as per capita expenditure, there are increasing number of campaigns organized each year by specific establishments, for example, National Eczema Associations, the PAN Foundation, and pharmaceutical organizations, which are envisaged to work to the advantage of several market vendors.

As the market for atopic dermatitis treatment progresses, industry stakeholders, pharmaceutical innovators, and healthcare providers are anticipated to focus on collaborative efforts to meet the evolving needs of patients and further drive advancements in this therapeutic landscape.

Key Companies Profiled Atopic Dermatitis Treatment Market:

Sanofi SA

Galderma SA

Allergan Plc.

Novartis

Bristol-Myers Squibb

Bayer AG

Meda Pharmaceuticals

Astellas Pharma Inc.

Anacor Pharmaceutical Inc.

Regeneron Pharmaceuticals

Valeant Pharmaceutical International Inc.

Act Now to Explore In-Depth Market Analysis: Get Exclusive Discount Now to Access Market Trends: <https://www.futuremarketinsights.com/checkout/3097>

Atopic Dermatitis Treatment Market by Category:

By Product:

- Corticosteroids
- Calcineurin Inhibitors
- Immunosuppressants
- Biologic Therapy
- PDE-4 Inhibitor
- Antibiotics
- Antihistamines
- Emollients

By Indication:

- Topical
- Oral
- Injectable

By End-User:

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- Mail Order Pharmacies
- Dermatology Clinics

By Region

- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific excluding Japan
- Japan
- Middle East and Africa (MEA)

Explore FMI's related ongoing Coverage on Healthcare Market Insights Domain

[Myelodysplastic Syndrome Treatment Market Size](#): The global market is poised to register a 5.9% CAGR, capturing a revenue share of US\$ 2,990.8 million in 2022, to reach US\$ 5,614.1 million by

2032.

[NGS Sample Preparation Market Share](#): The global market worth is expected to rise at a CAGR of 13.7% to US\$ 5.4 Billion by 2032.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Ankush Nikam

Future Market Insights, Inc.

+91 90966 84197

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/669172573>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.